nach oben

Erschienen in:

07.07.2016 | Original Research Article

Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment

verfasst von: Amit Khatri, Sandeep Dutta, Thomas C. Marbury, Richard A. Preston, Lino Rodrigues Jr, Haoyu Wang, Walid M. Awni, Rajeev M. Menon

Erschienen in: Clinical Pharmacokinetics | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

The direct-acting antiviral agent (DAA) combination of ombitasvir and paritaprevir (administered with ritonavir) with (3D regimen) or without (2D regimen) dasabuvir has shown very high efficacy rates in the treatment of chronic hepatitis C virus (HCV) infection. Renal impairment, a common comorbidity in patients with chronic HCV infection, can influence the pharmacokinetics of antiviral agents and hence their efficacy and safety profiles.

Objective

The aim of this study was to evaluate the influence of renal impairment on the pharmacokinetics and tolerability of the 3D and 2D regimens.

Methods

Overall, 24 subjects, six in each of four renal function groups (normal, mild, moderate, and severe), received a single dose of the 3D and 2D regimens in separate dosing periods. Plasma and urine were analyzed to assess the effect of renal impairment on drug exposure.

Results

DAA exposures changed by up to 21, 37, and 50 % in subjects with mild, moderate, and severe renal impairment, respectively, versus subjects with normal renal function. Ritonavir exposure increased with the degree of renal impairment (maximum 114 %). The half-lives of DAAs and ritonavir in subjects with renal impairment were generally comparable with those in healthy subjects. No safety or tolerability concerns arose in this study.

Conclusion

The 3D and 2D regimens do not require dose adjustment for patients with HCV infection and concomitant renal impairment.

Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18:52–61.CrossRefPubMed

Tsui JI, Vittinghoff E, Shlipak MG, Bertenthal D, Inadomi J, Rodriguez RA, et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med. 2007;167:1271–6.CrossRefPubMed

Butt AA, Wang X, Fried LF. HCV infection and the incidence of CKD. Am J Kidney Dis. 2011;57:396–402.CrossRefPubMed

Lucas GM, Jing Y, Sulkowski M, Abraham AG, Estrella MM, Atta MG, et al. Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis. 2013;208:1240–9.CrossRefPubMedPubMedCentral

Gilead Sciences Inc. Harvoni (ledipasvir and sofobuvir) tablets, for oral use. Approved prescribing information. Updated Mar 2015. Available at: http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf. Accessed 2 Nov 2015.

Genentech USA Inc. Pegasys (peginterferon alfa-2a) injection, for subcutaneous use. Approved prescribing information. Updated Mar 2015. Available at: http://www.gene.com/download/pdf/pegasys_prescribing.pdf. Accessed 2 Nov 2015.

Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother. 2015;59:979–87.CrossRefPubMedPubMedCentral

Pilot-Matias T, Tripathi R, Cohen D, Gaultier I, Dekhtyar T, Lu L, et al. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother. 2015;59:988–97.CrossRefPubMedPubMedCentral

Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97 % and 100 % sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(359–65):e1.

10.

Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983–92.CrossRefPubMed

11.

Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–82.CrossRefPubMed

12.

Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–603.CrossRefPubMed

13.

Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604–14.CrossRefPubMed

14.

AbbVie Ltd. Viekirax (ombitasvir, paritaprevir, ritonavir) tablets, for oral use. Summary of product characteristics. Updated 24 Sep 2015. Available at: https://www.medicines.org.uk/emc/medicine/29784. Accessed 2 Nov 2015.

15.

Hezode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385:2502–9.CrossRefPubMed

16.

Chayama K, Notsumata K, Kurosaki M, Sato K, Rodrigues L Jr, Setze C, et al. Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology. 2015;61:1523–32.CrossRefPubMed

17.

Kumada H, Chayama K, Rodrigues L Jr, Suzuki F, Ikeda K, Toyoda H, et al. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015;62:1037–46.CrossRefPubMedPubMedCentral

18.

AbbVie Inc. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), co-packaged for oral use. Approved prescribing information. Updated Oct 2015. Available at: http://www.rxabbvie.com/pdf/viekirapak_pi.pdf. Accessed 2 Nov 2015.

19.

US Department of Health and Human Services. Guidance for industry: pharmacokinetics in patients with impaired renal function—study design, data analysis, and impact on dosing and labeling, 2010. Available at: http://www.fda.gov/downloads/Drugs/Guidances/UCM204959.pdf. Accessed 2 Nov 2015.

20.

Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.CrossRefPubMed

21.

Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–70.

22.

Polepally AR, Dutta S, Hu B, Podsadecki TJ, Awni WM, Menon RM. Drug-drug interaction of omeprazole with the HCV direct-acting antiviral agents paritaprevir/ritonavir and ombitasvir with and without dasabuvir. Clin Pharm Drug Dev. 2016;5(4):269–77.CrossRef

23.

Committee for Medicinal Products for Human Use (CHMP). Note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function. London: European Medicines Agency; 2004.

24.

Hill A, van der Lugt J, Sawyer W, Boffito M. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials. AIDS. 2009;23:2237–45.CrossRefPubMed

25.

Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368:45–53.CrossRefPubMed

26.

Sullivan GJ, Rodrigues-Torres M, Lawitz E, Poordad F, Kapoor M, Campbell A, et al. ABT-267 combined with pegylated interferon alpha-2a/ribavirin in genotype 1 (GT1) HCV-infected treatment-naive subjects: 12 week antiviral and safety analysis. J Hepatol. 2012;56:S480.CrossRef

27.

Merck & Co. Inc. Victrelis (boceprevir) capsules, for oral use. Approved prescribing information. Updated Aug 2015. Available at: http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf. Accessed 2 Nov 2015.

28.

Vertex Pharmaceuticals Inc. Incivek (telaprevir) tablets, for oral use. Approved prescribing information. Updated Oct 2013. Available at: http://pi.vrtx.com/files/uspi_telaprevir.pdf. Accessed 2 Nov 2015.

29.

de Kanter CT, Drenth JP, Arends JE, Reesink HW, van der Valk M, de Knegt RJ, et al. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2014;53:409–27.CrossRefPubMed

30.

Thompson JR. Emerging therapeutic options for the management of hepatitis C infection. World J Gastroenterol. 2014;20:7079–88.CrossRefPubMedPubMedCentral

31.

Cortez KJ, Kottilil S. Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. Ther Adv Chronic Dis. 2015;6:4–14.CrossRefPubMedPubMedCentral

32.

Bristol-Myers-Squibb. Daklinza (daclatasvir) tablets, for oral use. Summary of product characteristics. Updated 24 Sep 2015. Available at: https://www.medicines.org.uk/emc/medicine/29129. Accessed 2 Nov 2015.

33.

Garimella T, Wang R, Luo WL, Hwang C, Sherman D, Kandoussi H, et al. Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment. Antivir Ther. 2015;20:535–43.CrossRefPubMed

34.

Janssen Products. Olysio (simeprevir) capsules, for oral use. Approved prescribing information. Updated Oct 2015. Available at: http://www.olysio.com/shared/product/olysio/prescribing-information.pdf. Accessed 2 Nov 2015.

Titel: Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment
verfasst von: Amit Khatri
Sandeep Dutta
Thomas C. Marbury
Richard A. Preston
Lino Rodrigues Jr
Haoyu Wang
Walid M. Awni
Rajeev M. Menon
Publikationsdatum: 07.07.2016
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 2/2017
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-016-0429-9

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment

Abstract

Background

Objective

Methods

Results

Conclusion

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies

Pharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis

Population Pharmacokinetics of Tracers: A New Tool for Medical Imaging?

Author’s Reply to Srinivas: “Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer”

Comment on: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study”

Comment on: “Modeling the Relationship between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer”